rabies vaccine (purified chick embryo cell vaccine)
Trade name: RabAvert
Vaccineapproved
Approved
Oct 20, 1997
The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. Transmission of rabies virus to humans typically occurs through a bite or scratch from an infectious animal, but exposure can occur through indirect contact with the saliva from an infectious individual. — Wikipedia
Clinical trial activity
42 trials · 31 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
20
Phase 3
12
Phase 4
8
Earliest trial started Feb 20, 2002 (NCT00031070)
Timeline
Indications
Approved for
Studied for
- Allergy and Immunology · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 4
- Encephalitis, Japanese · Phase 2
- Healthy Volunteers · Phase 2/Phase 3
- HIV Infections · Phase 2
- Malaria · Phase 3
- Malaria, Falciparum · Phase 1
- Pharmacological and Toxicological Phenomena · Phase 3
- Pre-Exposure Prophylaxis · Phase 2
- Primary Immunodeficiency Diseases · Phase 4
- Rabies · Phase 4
- Rabies virus · Phase 3
- Streptococcal Infections · Phase 1/Phase 2
- Virus Diseases · Phase 3
Mechanism of action
- Unspecified targetOTHER
Biological vaccine - induces immune response
- Lyssavirus rabiesImmunity, active
Lyssavirus rabies immunity, active
Approval history
- approvedOct 20, 1997
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRabies vaccine ↗
- ChEMBLCHEMBL2107909 ↗
Also known as
- imovax rabies
- imovax rabies
- rabavert
- rabavert
- rabies vaccine
- rabies vaccine
- rabies vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06048770 | Phase 1 | Sep 1, 2023 | Replicate Bioscience |
| NCT04882514 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2022 | Griffith University, University of Alberta |
| NCT04062669 | Phase 1 | Aug 15, 2019 | GlaxoSmithKline |
| NCT03264157 | Phase 2/Phase 3 (Phase 3) | Dec 8, 2017 | Bio Products Laboratory |
| NCT03145766 | Phase 2 | Apr 18, 2017 | Sanofi |
| NCT02564471 | Phase 4 | Apr 1, 2016 | Kansas State University, State University of New York, State University of New York, Syracuse, United States Army |
| NCT02547727 | N/A | Feb 1, 2016 | Chulalongkorn University |
| NCT02545517 | Phase 3 | Oct 1, 2015 | GlaxoSmithKline |
| NCT01641315 | N/A | Sep 1, 2015 | Chulalongkorn University |
| NCT02374814 | Phase 4 | Mar 24, 2015 | State University of New York, State University of New York, Syracuse, United States Army |
| NCT03093545 | N/A | Mar 1, 2015 | Biogentech Co.,LTD, Mahidol University, VINS Bioproducts Ltd. |
| NCT02288286 | Phase 3 | Nov 1, 2014 | Beijing Minhai Biotechnology Co., Ltd, Government of China |
| NCT02281396 | Phase 1 | Nov 1, 2014 | Beijing Minhai Biotechnology Co., Ltd, Government of China |
| NCT02276625 | Phase 2 | Oct 1, 2014 | Leiden University |
| NCT02177032 | Phase 3 | Jun 1, 2014 | Novartis |
| NCT01930357 | Phase 2 | Sep 1, 2013 | Sanofi, Sanofi-Aventis |
| NCT02538185 | Phase 1 | Aug 1, 2013 | University of Lausanne |
| NCT01877395 | Phase 2 | Jun 1, 2013 | Sanofi, Sanofi-Aventis |
| NCT02040090 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2013 | Kamada, Ltd., Prism Research |
| NCT01784874 | Phase 2 | Feb 1, 2013 | Sanofi, Sanofi-Aventis |
Showing 20 of 42 trials
Page 1 / 3
Organizations
Research & Development (31)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 8 | 8 | 3 | 2004 |
| Novartis | For profit | 6 | 6 | 3 | 2002 |
| Sanofi-Aventis | For profit | 5 | 0 | 2 | 2011 |
| Chulalongkorn University | Academic/Hospital | 4 | 4 | 1 | 2011 |
| GlaxoSmithKline | For profit | 4 | 3 | 2 | 2006 |
| Government of China | Government | 4 | 4 | 3 | 2012 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 3 | 2002 |
| United States Army | Government | 3 | 1 | 2 | 2006 |
| Beijing Minhai Biotechnology Co., Ltd | For profit | 2 | 0 | 2 | 2014 |
| Mahidol University | Academic/Hospital | 2 | 2 | 2 | 2002 |
| State University of New York | Academic/Hospital | 2 | 2 | 1 | 2015 |
| State University of New York, Syracuse | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Biogentech Co.,LTD | For profit | 1 | 0 | 1 | 2015 |
| Bio Products Laboratory | For profit | 1 | 1 | 1 | 2017 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2002 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 1 | 1 | 2009 |
| Chiron | For profit | 1 | 0 | 1 | 2002 |
| Griffith University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Kamada, Ltd. | For profit | 1 | 1 | 1 | 2013 |
| Kansas State University | Academic/Hospital | 1 | 0 | 1 | 2016 |
31 organizations
Page 1 / 2